Alpha Healthcare Acquisition Corp. (AHACU)

NEW YORK, March 27, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Alpha Healthcare Acquisition Corp. ("AHAC" or the "Company") (AHAC) relating to its proposed merger with Humacyte, Inc. Under the terms of the agreement, AHAC will acquire Humacyte through a reverse merger, with Humacyte emerging as a publicly traded company. The investigation focuses on whether Alpha Healthcare Acquisition Corp. and its Board of Directors violated securities laws and/or breached their fiduciary duties to the Company by 1) failing to conduct a fair process, 2) whether the transaction is properly valued, and 3) whether all material information has been disclosed.

Humacyte is a leader in regenerative medicine, growing human tissue in the lab that can be transplanted into any patient.

NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Alpha Healthcare Acquisition Corp. (the “Company”) announced today that holders of the units sold in the Company's initial public offering of 10,000,000 units completed on September 22, 2020 (the “offering”) may elect to separately trade the shares of Class A common stock and warrants included in the units commencing November 9, 2020. Any units not separated will continue to trade on the Nasdaq Capital  Market (the “Nasdaq”) under the symbol “AHACU”, and each of the shares of Class A common stock and warrants will separately trade on the Nasdaq under the symbols “AHAC” and “AHACW,” respectively. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company's transfer agent, in order to separate the units into shares of Class A common stock and warrants.